

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/041374

International filing date: 13 December 2004 (13.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/528,892
Filing date: 11 December 2003 (11.12.2003)

Date of receipt at the International Bureau: 31 January 2005 (31.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1274599

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 19, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/528,892

FILING DATE: *December 11, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/41374*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office



121103

18304 U.S. PTO

Please type a plus sign (+) inside this box → ☐PTO/SB/16 (02-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EU 861356146 US

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Jack		Elias		Woodbridge, CT	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
CCR5 blockage in emphysema					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number		<input type="text"/>		→ <div style="border: 1px solid black; padding: 2px; display: inline-block;">Place Customer Number Bar Code Label here</div>	
OR Type Customer Number here					
<input checked="" type="checkbox"/> Firm or Individual Name		Yale University, Office of Cooperative Research			
Address		433 Temple Street			
Address					
City		New Haven	State	CT	ZIP 06511
Country		USA	Telephone	(203) 436-8096	Fax (203) 436-8086
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages <input type="text" value="2"/>		<input type="checkbox"/> CD(s), Number <input type="text"/>	
<input checked="" type="checkbox"/> Drawing(s)		Number of Sheets <input type="text" value="26"/>		<input type="checkbox"/> Other (specify) <input type="text"/>	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees				\$80.00	
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <input type="text" value="25-0110"/>				\$80.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input type="checkbox"/> No.					
<input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: <input type="text" value="NHLBI HL 66571"/>					

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Olga Rivera

TELEPHONE

(203) 785-2005

Date 12/11/03REGISTRATION NO.
(if appropriate)
Docket Number:

1617

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Subject: CCR 5

From: Jack Elias <jack.elias@yale.edu>

Date: Wed, 10 Dec 2003 18:54:59 -0500

To: John Puziss <john.puziss@yale.edu>

CC: kathy bertier <kathleen.bertier@yale.edu>

John

Kathy from my office will be sending you a zip with a set of powerpoint slides demonstrating the effects of antibody and genetic neutralization/ablation of CCR 5 in the IL-13 and gamma interferon mice. (They are too big to send by E-mail). As you can see, both interventions decreased emphysema and inflammation (Th2-like in the case of IL-13 and Th1-like in the case of gamma). In the case of the IL-13 mice the elimination of CCR5 also increased survival. Other items to note are the ability of the CCR5 based interventions to

1. decrease TNF production
2. decrease IL-13 induced apoptosis (assessed by TUNEL staining)
3. decrease gamma interferon and IL-13-induced chemokine production including MCP-1, MIP-1alpha, MIP-1 beta, KC, IP-10

Thus we believe CCR 5 blockade can diminish IL-13 (Th2) and gamma interferon (Th1) induced inflammation, remodeling, emphysema and apoptosis

Call me if you have questions

Jack

Methods

CC10-IL-13 transgenic mice

CC10-IL-4 transgenic mice

CC10-rtTA-IL-13 transgenic mice

CC10-rtTA-IFN- γ transgenic mice

Anti - CCR5 monoclonal antibody

CCR5KO mice

From Jackson Lab

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

**Stimulation of CCR5 gene expression by IL-13, IL-4 and
gamma interferon in vivo**

IL-4	-					+
IL-13	-					+
IFN- γ (C57B/6)	-		+	+	+	
IFN- γ (Balb/c)	-		+	+	+	


CCR5

β -actin



Protocol for anti-CCR5 treatment

Anti-CCR5 antibody given every other day by i.p.
500µg per time.




Dox on



Sacrifice

Effect of anti-CCR5 on IL-13-induced increase in lung volume


Control IgG	+	-	+	-
Anti-CCR5	-	+	-	+
Dox	+	+	+	+
iIL-13	-	-	-	+




Effect of anti-CCR5 on IL-13-induced Inflammation




Effect of anti-CCR5 on IL-13 induced emphysema




Chord Length of Ind IL-13 mice: Effect of anti-CCR5




Effect of anti-CCR5 on the levels of BAL IL-13



Lung volume change of INF- γ mice after anti-CCR5 treatment



BAL total cell count of IFN- γ mice after anti-CCR5 treatment




Effect of anti-CCR5 on emphysema in CC10-IFN- γ Lungs


Ab control

Anti-CCR5


IFN- γ
(-)




IFN- γ
(+)



Effect of anti-CCR 5 on BAL IFN- γ Levels




Survival Days of CC1--IL-13 Mice with WT and Null Mutant CCR5 Loci




CCR5/13	n=	mean survival	P value
(+/-)(+)	9	140	
(+/-)(+)	10	165	0.0003
(-/-)(+)	5	191	0.0002


Role of CCR5 in IL-13-induced increase in lung size




Role of CCR5 in IL-13-induced BAL Inflammation



Role of CCR5 in IFN- γ -induced increase in lung size



Role of CCR5 in IFN- γ -induced inflammation




Role of CCR5 in IFN- γ -induced emphysema

CCR5 WT



CCR5 KO

IFN- γ
(-)





IFN- γ
(+)







Role of CCR5 in IFN- γ stimulation of KC and IP-10





Effect of anti-CCR5 on IL-13 induced emphysema




Percentage of TUNEL (+) cells on IL-13 Mouse Lung




Role of CCR5 in IL-13/ IFN- γ induced TNF- α production



Role of CCR5 in IL-4-induced increase in lung size



Role of CCR5 in IL-4-induced BAL inflammation



TUNEL Staining in iIL-13 Mouse Lung

Treatment; Control IgG

Anti-CCR5

IL-13
(-)





IL-13
(+)



Role of CCR5 in CC10-IL-4 Lung

CCR5 (+/+)

CCR5 KO





IL-4
(-)

IL-4
(+)


Role of CCR5 in IL-13-induced lung phenotype

CCR5 (+/+)

CCR5 KO



IL-13
(-)



IL-13
(+)